Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Profit After Tax (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Profit After Tax for 14 consecutive years, with -$32.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax rose 37.92% year-over-year to -$32.4 million, compared with a TTM value of -$136.3 million through Dec 2025, up 26.82%, and an annual FY2025 reading of -$136.3 million, up 26.82% over the prior year.
  • Profit After Tax was -$32.4 million for Q4 2025 at Fate Therapeutics, roughly flat from -$32.2 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$18.9 million in Q1 2023 and bottomed at -$83.6 million in Q3 2022.
  • Average Profit After Tax over 5 years is -$48.9 million, with a median of -$46.4 million recorded in 2023.
  • The sharpest move saw Profit After Tax surged 71.26% in 2023, then crashed 154.25% in 2024.
  • Year by year, Profit After Tax stood at -$68.7 million in 2021, then grew by 17.9% to -$56.4 million in 2022, then increased by 21.72% to -$44.1 million in 2023, then decreased by 18.2% to -$52.2 million in 2024, then skyrocketed by 37.92% to -$32.4 million in 2025.
  • Business Quant data shows Profit After Tax for FATE at -$32.4 million in Q4 2025, -$32.2 million in Q3 2025, and -$34.1 million in Q2 2025.